- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01256125
Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.
December 7, 2010 updated by: Sun Yat-sen University
Therapeutic Effects of Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.
Allogene MSCs transplantation will be performed in patients with chronic liver diseases through peripheral vein and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.
Study Overview
Status
Unknown
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
GuangZhou, Guangdong, China, 510630
- Recruiting
- Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Liang Peng, Dr.
- Phone Number: +86-013533978874
- Email: pzp33@hotmail.com
-
Contact:
- Jing Liu, Master
- Phone Number: +86-013556051920
- Email: diudiu1203@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease and so on.
Description
Inclusion Criteria:
- chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease.
- age: 15-65 years old.
Exclusion Criteria:
- pregnant women and women in lactation.
- other systems and organs disfunction
- space-occupying lesion were found in liver.
- concurrent infection with HIV and other immunodeficiency diseases.
- DIC and active bleeding were confirmed.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Allogene MSCs transplantation
Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
|
control
only medical treatments were performed in patients with chronic liver diseases.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation through peripheral vein.
Time Frame: 1-8 weeks after transplantation
|
1-8 weeks after transplantation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Long-term follow-up of Allogene MSCs transplantation through peripheral vein.
Time Frame: 3-60 months
|
3-60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Study Registration Dates
First Submitted
December 7, 2010
First Submitted That Met QC Criteria
December 7, 2010
First Posted (Estimate)
December 8, 2010
Study Record Updates
Last Update Posted (Estimate)
December 8, 2010
Last Update Submitted That Met QC Criteria
December 7, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SunYat-sen U 11-5-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allogene MSCs Transplantation
-
Sun Yat-sen UniversityUnknownChronic Liver Diseases Patients | Allogene Transplantation | Through Portal Vein by Ultrasound GuidingChina
-
Chinese PLA General HospitalCompleted
-
Chinese PLA General HospitalGansu Provincial Maternity and Child-Care HospitalUnknownMSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision
-
Chinese PLA General HospitalUnknownMSCs Derived Pleiotropic Factors on Wound Healing in Endonasal Surgeries
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland